Daniel Morgensztern, MD, Meghan J. Campo, MD, Suzanne E

Slides:

Advertisements

Similar presentations

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Advertisements

Lung Cancer Tumour Markers

Silvestri Gerard A. , MD, FCCP, Rivera M. Patricia , MD, FCCP CHEST

Advances in Molecular Biology of Lung Disease

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Targeting signal transduction

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Activation of Oncogenic Pathways in Idiopathic Pulmonary Fibrosis

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R

MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values Geun Dong Lee, MD, PhD, Seung Eun Lee, MD,

ALK FISH and IHC: You Cannot Have One without the Other

Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M

Ground glass opacities: Imaging, pathology, and gene mutations

Chasing Therapeutic Targets in Thymic Malignancies: Finding Needles in the Haystack to Frame a Comprehensive Canvas? Nicolas Girard, MD Journal of Thoracic.

Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification Justin.

Scientific Advances in Lung Cancer 2015

Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung.

G48A, a New KRAS Mutation Found in Lung Adenocarcinoma

Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer Roberto Ferrara, MD, Nathalie Auger, MD, Edouard Auclin,

Axl Receptor Axis: A New Therapeutic Target in Lung Cancer

Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication

The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC Si-Yang Liu, MD, Lan-Ying Gou, MD, An-Na Li, MD, Na-Na Lou, MMed, Hong-Fei.

Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer Vassiliki Papadimitrakopoulou,

Scientific Advances in Lung Cancer 2015

Schematic view of Trk receptors signalling, showing the three major pathways involved in cell differentiation and survival. Schematic view of Trk receptors.

Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated.

Megan B. Barnet, BS, M. B. B. S. , Sandra O’Toole, PhD, Lisa G

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung.

Inflammation, Epithelial to Mesenchymal Transition, and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance Kostyantyn Krysan, PhD,

Electronic Updates for JTO Readers

Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non–Small Cell Lung Cancer Alexa B. Schrock, PhD, Allison.

Opioids and neovascularization; pro or anti?

PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer Denis Soulières, MD, Fred R.

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping

Nat. Rev. Urol. doi: /nrurol

BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer

Vascular Endothelial Growth Factor (VEGF) Pathway

Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening–Detected Lung Cancers Carla Verri, MSc, Cristina Borzi, MSc, Todd Holscher,

Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non–Small-Cell Lung.

The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing Marieke Hylebos, MSc, Guy Van Camp, PhD, Jan P van.

Pyrosequencing Analysis of EGFR and KRAS Mutations in EUS and EBUS-Derived Cytologic Samples of Adenocarcinomas of the Lung Jos A. Stigt, MD, Nils A.

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET- Mutated Tumor Marc-Antoine Benderra, MD, Sandrine Aspeslagh, PhD, Sophie.

Clinicopathologic Features of Advanced Squamous NSCLC

Matthias Scheffler, MD, Michaela A

Volume 73, Issue 1, Pages 5-7 (January 2008)

Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench Kenichi Suda, MD, PhD, Paul A. Bunn,

Inderpal S. Sarkaria, MD, Maureen F

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis Bin-Chi Liao,

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

Yan Feng, MD, Praveena S. Thiagarajan, PhD, Patrick C. Ma, MD

MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values Geun Dong Lee, MD, PhD, Seung Eun Lee, MD,

Mitotic Inhibitors Journal of Thoracic Oncology

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

MET Expression Plays Differing Roles in Non–Small-Cell Lung Cancer Patients with or without EGFR Mutation Ling Huang, MS, She-Juan An, PhD, Zhi-Hong.

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Simon Ekman, MD, PhD, Murry W. Wynes, PhD, Fred R. Hirsch, MD, PhD

Genetic Changes in Squamous Cell Lung Cancer: A Review

Platelet-derived growth factor (PDGF) signalling pathway.

Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non–Small-Cell Lung Cancer Charles M.

Christina S. Baik, MD, MPH, Marc C. Chamberlain, MD, Laura Q. Chow, MD

Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma Filippo Lococo, MD,

Effects of PARP inhibition on the DNA damage response.

Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018 Jordi Remon, MD, Myung-Ju Ahn, MD, Nicolas Girard, MD, PhD, Melissa Johnson,

Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping Ibiayi Dagogo-Jack, MD, Justin.

The Current Role of Whole Brain Radiation Therapy in Non–Small Cell Lung Cancer Patients Gokoulakrichenane Loganadane, MD, Lizza Hendriks, MD, PhD, Cécile.

Presentation transcript:

Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014 Daniel Morgensztern, MD, Meghan J. Campo, MD, Suzanne E. Dahlberg, PhD, Robert C. Doebele, MD, PhD, Edward Garon, MD, David E. Gerber, MD, Sarah B. Goldberg, MD, Peter S. Hammerman, MD, PhD, Rebecca S. Heist, MD, Thomas Hensing, MD, Leora Horn, MD, Suresh S. Ramalingam, MD, Charles M. Rudin, MD, PhD, Ravi Salgia, MD, PhD, Lecia V. Sequist, MD, Alice T. Shaw, MD, PhD, George R. Simon, MD, Neeta Somaiah, MD, David R. Spigel, MD, John Wrangle, MD, David Johnson, MD, Roy S. Herbst, MD, PhD, Paul Bunn, MD, Ramaswamy Govindan, MD Journal of Thoracic Oncology Volume 10, Issue 1, Pages S1-S63 (January 2015) DOI: 10.1097/JTO.0000000000000405 Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Potential targetable oncogenes by histology subtype. EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; DDR2, discoidin domain receptor tyrosine kinase 2; FGFR1, fibroblast growth factor receptor 1; KRAS, Kirsten rat sarcoma viral oncogene homolog; MET, MET proto-oncogene; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha; PTEN, phosphatase and tensin homology deleted on chromosome 10; RET, ret proto-oncogene; SCLC, small-cell lung cancer. Journal of Thoracic Oncology 2015 10, S1-S63DOI: (10.1097/JTO.0000000000000405) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Chromatin-modifying enzymes. MEK, mitogen-activated protein kinase kinase; ERK, extracellular signal–regulated kinase; PHD, plant homeodomain; PI3K, phosphatidylinositol 3-kinase; PWWP, proline-tryptophan-tryptophan-proline. Journal of Thoracic Oncology 2015 10, S1-S63DOI: (10.1097/JTO.0000000000000405) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 ROS1, NTRK1, and RET inhibitors. MPRIP, myosin phosphatase Rho interacting protein; NTRK1, neurotrophic tyrosine kinase, receptor, type 1; EZR, ezrin; ROS, ROS proto-oncogene 1; AKT, v-akt murine thymoma viral oncogene homolog; KIF, kinesin family member 5B; and RET, ret proto-oncogene. Journal of Thoracic Oncology 2015 10, S1-S63DOI: (10.1097/JTO.0000000000000405) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 KRAS Mutations in NSCLC. ERK, extracellular signal-regulated kinase; GDP, guanosine 5’-diphosphate; GF, growth factor; GTP, guanosine 5’-triphosphate; JNK, Jun N-terminal kinase; MEK, MAP (mitogen-activated protein) kinase; PDK1, phosphoinositide-dependent kinase-1; PI3K, phosphatidylinositol 3-kinase; PKC, Protein kinase C; RAS, rat sarcoma; RTK, receptor tyrosine kinase; SOS, son of sevenless. Journal of Thoracic Oncology 2015 10, S1-S63DOI: (10.1097/JTO.0000000000000405) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 5 Mitotic/cyclin inhibitors. NHEJ, non-homologous end joining; HR, homologous recombination. Journal of Thoracic Oncology 2015 10, S1-S63DOI: (10.1097/JTO.0000000000000405) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 6 PARP inhibition: Mechanism of action (reproduced from Oncology Live, 2013, permission requested). BER, base excision repair; NAD, nicotinamide adenine dinucleotide; PARP, Poly(ADP-ribose) polymerase. Journal of Thoracic Oncology 2015 10, S1-S63DOI: (10.1097/JTO.0000000000000405) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions